Loading...
Loading...
AGIO| Name | Value |
|---|---|
| Revenues | 8.6M |
| Cost of Revenue | 3.1M |
| Gross Profit | 5.5M |
| Operating Expense | 111.3M |
| Operating I/L | -105.8M |
| Other Income/Expense | 9.7M |
| Interest Income | 8.1M |
| Pretax | -96.1M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -96.1M |
Agios Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery and development of medicines in cellular metabolism and related biological areas. The company's primary revenue comes from the commercialization of PYRUKYND (mitapivat), an activator of pyruvate kinase enzymes for the treatment of hemolytic anemias. Additionally, they are developing AG-946, currently in Phase I clinical study, for the treatment of hemolytic anemias and other indications.
